tofacitinib (Chong Kun Dang)

Evidence outlook · lead readout

NCT03868072 · Rheumatoid Arthritis

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT03868072: This was a randomized crossover study against an approved active comparator, but it was not blinded and measured only blood drug levels rather than any clinical outcome, and results have not been posted. This kind of study exists to support generic approval, not to demonstrate therapeutic benefit.